These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28534812)

  • 1. Understanding the Complex Patterns Observed during Hepatitis B Virus Therapy.
    Carracedo Rodriguez A; Chung M; Ciupe SM
    Viruses; 2017 May; 9(5):. PubMed ID: 28534812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus kinetics and mathematical modeling.
    Perelson AS; Ribeiro RM
    Semin Liver Dis; 2004; 24 Suppl 1():11-6. PubMed ID: 15192796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling complex decay profiles of hepatitis B virus during antiviral therapy.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Hepatology; 2009 Jan; 49(1):32-8. PubMed ID: 19065674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and virological mechanisms of HBV drug resistance.
    Locarnini S; Mason WS
    J Hepatol; 2006 Feb; 44(2):422-31. PubMed ID: 16364492
    [No Abstract]   [Full Text] [Related]  

  • 6. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel viral and host targets to cure hepatitis B.
    Ko C; Michler T; Protzer U
    Curr Opin Virol; 2017 Jun; 24():38-45. PubMed ID: 28433762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Hepatitis B Virus Infection Induces Cytopathic Effects in Primary Human Hepatocytes, and Can Be Partially Reversed by Antiviral Therapy.
    Zai W; Hu K; Ye J; Ding J; Huang C; Li Y; Fang Z; Wu M; Wang C; Chen J; Yuan Z
    Microbiol Spectr; 2022 Feb; 10(1):e0132821. PubMed ID: 35171034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
    J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Intracellular Model of Hepatitis B Viral Infection: An In Silico Platform for Comparing Therapeutic Strategies.
    Fatehi F; Bingham RJ; Dykeman EC; Patel N; Stockley PG; Twarock R
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33374798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The review of differential equation models of HBV infection dynamics.
    Li M; Zu J
    J Virol Methods; 2019 Apr; 266():103-113. PubMed ID: 30716348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.
    Lewin S; Walters T; Locarnini S
    Antiviral Res; 2002 Sep; 55(3):381-96. PubMed ID: 12206877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of lamivudine in the treatment of chronic hepatitis B virus infection.
    Hagmeyer KO; Pan YY
    Ann Pharmacother; 1999 Oct; 33(10):1104-12. PubMed ID: 10534223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute hepatitis B and reactivation of hepatitis B.
    Jindal A; Kumar M; Sarin SK
    Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
    Shi M; Sun WL; Hua YY; Han B; Shi L
    PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.